Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Sotatercept (Winrevair)

decorative image of the issue cover

Published February 19, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Winrevair (sotatercept), 45 mg or 60 mg, powder and solvent for injectable solution.
  • Indication: In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with WHO Group 1 PAH and Functional Class II or III.